Cocaine Use Disorder (CUD), like all other stimulant use disorders, remains a challenging condition to treat, particularly in the absence of FDA-approved pharmacotherapies. While contingency management (CM) is considered first-line treatment and has demonstrated strong evidence for efficacy, it remains underutilized due to financial, philosophical, and logistical barriers. Off-label use of psychostimulants has emerged as a potential therapeutic strategy, especially in patients with comorbid…
